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Background: Fluticasone furoate (FF) is a novel, once-daily inhaled corticosteroid (ICS) that has been shown to
improve lung function vs. placebo in asthma patients. This study evaluated the efficacy and safety of FF 50 mcg
compared with placebo in asthma patients uncontrolled by non-ICS therapy.
Methods: This 12-week, multicentre, randomized, double-blind, placebo-controlled, parallel-group, phase III study
randomized 248 patients (aged ≥12 years) to once-daily FF 50 mcg administered via the ELLIPTA™a dry powder
inhaler or placebo. The primary endpoint was change from baseline in pre-dose evening trough forced expiratory
volume in one second (FEV1). Secondary endpoints were change from baseline in percentage of rescue-free 24-h
periods (powered), evening and morning peak expiratory flow, symptom-free 24-h periods and withdrawals due to
lack of efficacy. Other endpoints included Asthma Control Test™, Asthma Quality of Life Questionnaire and ELLIPTA
ease of use questions. Safety was assessed throughout the study.
Results: There was a significant difference in evening trough FEV1 between FF 50 mcg and placebo (treatment
difference: 120 mL; p = 0.012). There was also a significant difference in rescue-free 24-h periods (11.6%; p = 0.004)
vs. placebo. There were numerically greater improvements with FF vs. placebo for all remaining secondary endpoints.
The incidence of adverse events was lower with FF (31%) than with placebo (38%); few were treatment-related
(FF 50 mcg: n = 1, <1%; placebo: n = 4, 3%).
Conclusion: FF 50 mcg once daily significantly improved FEV1 and percentage of rescue-free 24-h periods
experienced over 12 weeks vs. placebo, and was well tolerated.
Trial registration: www.clinicaltrials.gov, registration number: NCT01436071
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Failure to achieve asthma control can impact patients’
daily lives and results in persistent symptoms, more fre-
quent exacerbations and absenteeism from work and
school [1,2]. Inhaled corticosteroids (ICS) are the most
effective anti-inflammatory treatments for all severities
of persistent asthma [3-5]. Patient adherence is a key
component to the overall success of asthma treatment, and
it has been demonstrated that compliance with a once-daily
ICS is better than with a twice-daily regimen [6].* Correspondence: obyrnep@mcmaster.ca
1Michael G DeGroote School of Medicine, Hamilton, ON, Canada
Full list of author information is available at the end of the article
© 2014 O'Byrne et al.; licensee BioMed Centra
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.Fluticasone furoate (FF) is a novel once-daily ICS treat-
ment for asthma [7-11], which is also used in combination
with the long-acting β2-agonist (LABA) vilanterol (VI) for
the once-daily treatment of asthma and COPD [12-14].
Animal and human pharmacology studies show that FF
has a long duration of action and prolonged retention in
the lung, suggesting it is appropriate for once-daily dosing
[15,16]. As part of the overall FF clinical development
program, a dose-ranging study (25–200 mcg doses of
FF) showed that FF 50 mcg administered over 8 weeks
was the minimum dose required to achieve significant
improvements in evening trough forced expiratory volumel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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periods compared with placebo [7].
This 12-week study sought to evaluate the efficacy and
safety of once-daily FF 50 mcg dosed in the evening in
asthma patients aged ≥12 years who were uncontrolled
on short-acting β2-agonists (SABA) and/or leukotriene
modifying agent. One other study with FF 50 mcg has
been published [7], which was an 8-week dose ranging
study. Two phase III studies of longer duration (of which
this is one) comparing FF 50 mcg with placebo have
been conducted in SABA only patients, to determine
whether FF 50 mcg is a suitable starting dose for asthma
patients not already using a controller medication. Prelim-
inary results have been presented in abstract form [17].
Methods
Patients
Patients were aged ≥12 years with a diagnosis of asthma
[4] made at least 12 weeks prior to screening and being
treated with non-ICS controllers (a SABA alone or in
combination with a leukotriene modifying agent); the
use of ICS or LABA was not permitted for at least
4 weeks prior to the initial screening visit. Patients had
to demonstrate a best FEV1 of ≥60% of the predicted
normal value and ≥12% and 200 mL reversibility of FEV1
within 10–40 minutes following 2–4 inhalations of albute-
rol/salbutamol. Eligible patients also had no evidence of
oral/oropharyngeal candidiasis.
At the end of a 2-week run-in period, patients were
randomized if they had an evening pre-dose FEV1 ≥ 60%
of the predicted normal value and, on at least 4 of the
last 7 consecutive days of the run-in period, had docu-
mented use of albuterol/salbutamol and/or exhibited
asthma symptoms and completed all morning and evening
eDiary entries. Written informed consent was obtained
from each patient.
Study design and treatments
This was a phase III, multicentre, randomized, placebo-
controlled, double-blind, parallel-group study conducted
between 12th September 2011 and 7th August 2012 at
19 centers in four countries (Mexico, Peru, Russia, United
States) (GSK study number FFA115283; www.clinical-
trials.gov registration number NCT01436071). The study
was approved by local ethics committees and conducted
in accordance with the Declaration of Helsinki and Good
Clinical Practice guidelines.
Patients were randomized (1:1) to receive FF 50 mcg
or placebo for a period of 12 weeks; both treatments
were administered by the ELLIPTA dry powder inhaler
once daily in the evening. Patients were randomized in
accordance with a central randomization schedule gener-
ated by the sponsor using a validated computerized system
(RandAll [GlaxoSmithKline, UK]), after a telephone callto the Registration and Medication Ordering System
(RAMOS [GlaxoSmithKline, UK]). Both patients and
investigators were blinded to treatment allocations. Treat-
ment compliance was assessed by reviewing the dose
counter on the ELLIPTA device. All patients received
albuterol/salbutamol, to be used as needed throughout
the run-in and treatment periods; no other asthma
medications were permitted. The following non-asthma
medications were permitted during the study: decon-
gestants; intranasal and topical corticosteroids; immu-
notherapy; short- and long-acting antihistamines; and
antihistamine eye drops.
Outcome measurements
The primary efficacy endpoint was change from baseline
in pre-dose evening (trough) FEV1 at Week 12. FEV1
measurements were performed in the clinic at Weeks 2,
4, 8 and 12 and were made within 1 h of the time FEV1
was measured at baseline and approximately 24-h after
the last evening dose of medication.
The powered secondary endpoint was change from
baseline in the percentage of rescue-free 24-h periods
during the 12-week treatment period. Other secondary
endpoints were: change from baseline in daily evening
and morning peak expiratory force (PEF) averaged over
the 12-week treatment period; change from baseline in
the percentage of symptom-free 24-h periods during the
12-week treatment period; and number of withdrawals
from study due to lack of efficacy. PEF measurements,
symptoms and use of rescue medication were recorded
daily using an eDiary.
Other selected endpoints included: change from baseline
in Asthma Control TestTM (ACT) score at Week 12; per-
centage of patients controlled (defined as having an ACT
score ≥20) at Week 12; change from baseline in Asthma
Quality of Life Questionnaire (AQLQ) + 12 Total score at
Week 12; and ease of use questions on the ELLIPTA dry
powder inhaler at the end of 4 weeks of treatment.
Safety evaluations
Safety endpoints included the incidence of adverse events
(AEs; coded using the Medical Dictionary for Regulatory
Activities dictionary) and severe asthma exacerbations
throughout the 12-week treatment period. A severe
exacerbation was defined as deterioration of asthma
requiring the use of systemic/oral corticosteroids for
at least 3 days or an inpatient hospitalization or emergency
department visit due to asthma that required systemic cor-
ticosteroids. Oropharyngeal examination was performed
throughout the duration of the treatment period.
Statistical analysis
A total of 220 randomized patients were expected to pro-
vide 104 evaluable patients per arm, giving 94% power to
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placebo groups in evening trough FEV1, with significance
declared at the two-sided 5% level. This also provided 95%
power to detect a difference of 15% between FF 50 mcg
and placebo groups in the change from baseline in
percentage of rescue-free 24-h periods, with signifi-
cance declared at the two-sided 5% level. The overall
power of the study to detect treatment differences
between FF 50 mcg and placebo for the primary and
powered secondary endpoints was 90%.
The primary efficacy endpoint was the change from
baseline in pre-dose evening (trough) FEV1 at the end of
treatment (Week 12). This was analysed using an Analysis
of Covariance (ANCOVA) model, which allowed for effectsFigure 1 Patient disposition. aMain reason was patients did not meet inc
meet continuation criteria: 36(8%); AE = adverse event; FF = fluticasone furodue to baseline FEV1, region, sex, age and treatment group.
Last Observation Carried Forward was used to impute
missing data. A supporting analysis was performed using a
repeated measures model. Powered secondary, secondary
and other endpoint comparisons were also analyzed using
ANCOVA, with the exception of withdrawals due to
lack of efficacy (analyzed using Fisher’s Exact test) and
the percentage of patients controlled (ACT score ≥20;
analyzed using logistic regression).
The safety population comprised all patients randomized
to treatment and who received at least one dose of
study medication. The intent-to-treat (ITT) population
comprised all patients in the safety population except
for 20 (10 from each treatment arm) patients excludedlusion/exclusion criteria: 151(34%); bmain reason was patients did not
ate; ITT = intent-to-treat; OD = once daily; PP = per protocol.
Table 1 Patient demographics and lung function at screening/baseline (intent-to-treat population)
Placebo OD PM (N = 111) FF 50 mcg OD PM (N = 111)
Age, mean (SD) 33.8 (13.90) 36.7 (16.16)
Age range, years 12–68 12–77
Female, n (%) 70 (63) 63 (57)
Race, n (%)
American Indian or Alaska Native 59 (53) 45 (41)
White 29 (26) 42 (38)
American Indian or Alaska Native and White 21 (19) 24 (22)
Other 2 (2) 0
Screening characteristics, mean (SD)
Pre-bronchodilator FEV1 (L) 2.527 (0.6940) 2.452 (0.6843)
Percent predicted FEV1, % 77.33 (12.884) 74.71 (9.493)
Post-bronchodilator FEV1 (L) 3.139 (0.8784) 3.047 (0.8443)
Percent reversibility FEV1, % 24.32 (10.368) 24.77 (9.906)
Baseline characteristics, mean (SD)
Pre-bronchodilator FEV1* (L) 2.712 (0.8305) 2.669 (0.8172)
Percent predicted FEV1*, % 82.30 (14.115) 80.85 (12.277)
Rescue-free 24-h periods, % 7.5 (21.04) 10.2 (21.49)
Symptom-free 24-h periods, % 3.2 (12.73) 5.0 (14.53)
PM PEF (L/min) 356.8 (120.53) 359.0 (121.14)
AM PEF (L/min) 350.3 (115.89) 349.2 (117.21)
*Assessed in 110 patients from each treatment arm; FEV1 = forced expiratory volume in one second; FF = fluticasone furoate; OD = once daily; PEF = peak
expiratory flow PM = evening; SD = standard deviation.
Table 2 Results for primary, secondary and selected other endpoints (intent-to-treat population)
Endpoint Placebo OD
PM (N = 111)
FF 50 mcg OD
PM (N = 111)
n Mean (SE) n Mean (SE) Difference (95% CI)
Pre-dose evening FEV1
a, L Primary 106 0.038 (0.0333) 108 0.157 (0.0330) 0.120* (0.026, 0.213)
Rescue-free 24-h periodsb, % Secondary (powered) 110 17.1 (2.78) 111 28.7 (2.77) 11.6*(3.8, 19.4)
Evening PEFb, L/min Secondary 110 19.5 (3.72) 111 22.8 (3.70) 3.3 (−7.2, 13.7)
Morning PEFb, L/min Secondary 110 22.9 (3.65) 111 34.5 (3.64) 11.6 (1.4, 21.9)
Symptom-free 24-h periodsb, % Secondary 110 14.0 (2.49) 111 22.6 (2.47) 8.6 (1.6, 15.6)
Number of patients Number of patients
Withdrawal due to lack of efficacyb, % Secondary 14 6
n Mean (SE) n Mean (SE) Difference (95% CI)
Asthma Control Test™ (ACT) scorea Other 92 4.0 (0.39) 100 6.2 (0.38) 2.2 (1.1, 3.3)
n Number of patients n Number of patients Odds Ratio (95% CI)
Patients with ACT score ≥20a, % Other 92 55 100 69 1.88 (0.97, 3.65)
n Mean (SE) n Mean (SE) Difference (95% CI)
Total Asthma Quality of Life Questionnaire
(AQLQ) + 12 scorea
Other 92 0.84 (0.097) 100 1.30 (0.093) 0.45 (0.18, 0.72)
Change from baseline: aat Week 12, bduring or averaged over Weeks 1–12. *statistically significant. FEV1 = forced expiratory volume in one second; PEF = peak
expiratory flow; FF = fluticasone furoate; OD = once daily; PM = evening; SE = standard error; CI = confidence interval.
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during a previous study. The per protocol population
comprised all ITT patients who did not have any full
protocol deviations.
In order to account for multiplicity across the key end-
points, a step-down closed testing procedure was applied
for the primary and secondary endpoints whereby failure
to achieve significance (p < 0.05) for the primary treatment
comparison (FF 50 mcg vs. placebo), at any point in the
hierarchy, meant that all tests lower down in the hierarchy
were interpreted as descriptive only. The hierarchy was
as follows: (1) evening trough FEV1; (2) rescue-free 24-h
periods; (3) evening PEF; (4) morning PEF; (5) symptom-
free 24-h periods; and (6) withdrawals due to lack of
efficacy. If significance was achieved at each stage ofFigure 2 Adjusted treatment differences for the change from baselin
(intent-to-treat population). *Data were analysed using a closed step-down
in the hierarchy meant that statistical significance could not be inferred for sub
treatment difference; dashed lines indicate differences which are not significan
endpoints); FEV1 = forced expiratory volume in one second; PEF = peak expira
Questionnaire; CI = confidence interval.the hierarchy, then all other efficacy endpoints were
tested without further multiplicity adjustment.
Results
Study population
Of 449 patients screened, 248 were randomized, of whom
242 comprised the safety population and 222 comprised
the ITT population. Within the ITT population, 90 (81%)
placebo and 100 (90%) FF 50 mcg patients completed the
study (Figure 1). Mean age, percentage of female patients
and screening/baseline characteristics of lung function
were similar between treatment groups (Table 1), with a
baseline mean% predicted FEV1 of 81.58% in the ITT
population. The majority of patients were of Hispanic/
Latino ethnicity (73% placebo; 64% FF 50 mcg). Overalle for primary, and selected secondary and other endpoints
statistical hierarchy, whereby failure to achieve significance at any point
sequent endpoints in the hierarchy. Solid lines indicate a significant
t (evening PEF) or for which significance cannot be inferred (all remaining
tory flow; ACT = Asthma Control Test; AQLQ = Asthma Quality of Life
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the study using the dose counter on the DPI) was high
and similar between treatment groups, at 97.7% in the
placebo group and 99.0% in the FF 50 mcg group.
Efficacy
For the primary endpoint, the change from baseline
evening trough FEV1 at Week 12 was 157 mL with FF
50 mcg and 38 mL with placebo; the treatment difference
of 120 mL (p = 0.012) was statistically significant (Table 2;
Figure 2). Repeated measures analysis demonstrated that
trough FEV1 was consistently greater with FF 50 mcg vs.
placebo throughout the study period (Figure 3). Support-
ing analysis of the per protocol population was similar
(treatment difference in favor of FF 50 mcg: 131 mL [95%
CI: 38, 224]; p = 0.006).
For the powered secondary endpoint, there was a statis-
tically significant increase from baseline in the percentage
of rescue-free 24-h periods (28.7%) compared with pla-
cebo (17.1%; treatment difference of 11.6%; p = 0.004)
(Table 2, Figure 2); this improvement equated to an add-
itional 0.8 rescue-free 24-h periods per week with FF 50
mcg treatment. Rescue-free 24-h periods were consistently
greater over the course of the study with FF 50 mcg com-
pared with placebo (Figure 4A).
The results for selected secondary and other endpoints
are summarized in Table 2 and Figure 2. The change from
baseline in evening PEF over the 12-week treatment
period was increased with FF 50 mcg (22.8 L/min) and
placebo (19.5 L/min), but the treatment difference
(3.3 L/min) was not statistically significant (p = 0.536).
In accordance with the pre-defined statistical hierarchy
of endpoints, significance could not be inferred for the
remaining endpoints. Increase from baseline in morning
PEF was numerically greater for FF 50 mcg (34.5 L/min)Figure 3 Repeated measures analysis of change from baseline in trou
OD = once daily; LS = least squares; CI = confidence interval.compared with placebo treatment (22.9 L/min; treatment
difference of 11.6 L/min). Likewise, the increase from
baseline in the percentage of symptom-free 24-h periods
was also numerically greater for FF 50 mcg (22.6%) com-
pared with placebo treatment (14.0%; treatment difference
of 8.6%), which equates to an additional 0.6 symptom-free
24-h periods per week with FF 50 mcg treatment. The
greatest improvement in symptom-free 24-h periods with
FF 50 mcg compared with placebo was observed during
the last 4 weeks of the study (Figure 4B). A numerically
greater proportion of patients in the placebo group with-
drew due to lack of efficacy (14%) compared with patients
in the FF 50 mcg group (6%) (Figure 5).
Numerically greater increases in ACT score, propor-
tion of patients with an ACT score ≥20 and change from
baseline in Total AQLQ(+12) score were observed for
FF 50 mcg compared with placebo (Table 2; Figure 2).
At baseline, most patients were able to use the ELLIPTA
inhaler correctly after being instructed once (98% FF 50
mcg; 96% placebo). At Week 4, most patients rated the
ELLIPTA inhaler as ‘easy/very easy’ to use (97%) and
‘easy/very easy’ to see how many doses of medication
were left in the inhaler (95%).
Safety assessments
Within the safety population, the overall incidence of
on-treatment AEs was similar for placebo (38%) and FF
50 mcg (31%); the most frequently occurring on-treatment
AEs were headache, nasopharyngitis, pharyngitis and influ-
enza (Table 3). The incidence of treatment-related AEs was
low in both treatment groups: 3% (n = 4) with placebo
(pharyngitis, n = 1; upper respiratory tract infection, n = 1;
dysgeusia and headache, n = 1; urticaria, n = 1); <1% (n = 1)
with FF 50 mcg (contusion, n = 1). One patient in the
placebo group was withdrawn from the study followinggh FEV1 (L) (intent-to-treat population). FF = fluticasone furoate;
AB
Figure 4 Change from baseline in percentage of rescue-free (A) and symptom-free (B) 24-h periods during the 12-week study period
(intent-to-treat population). FF = fluticasone furoate; OD = once daily; SE = standard error.
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special interest were reported: hypersensitivity (placebo),
oropharyngeal pain (FF 50 mcg) and skeletal injury (FF 50
mcg). However, none of these were considered related to
study medication or resulted in study withdrawal.
Two serious AEs were reported (traffic accident, placebo;
perforated appendix, FF 50 mcg); neither was fatal nor
considered to be treatment related, and both patients
completed the study. Three patients in the placebo group
experienced severe asthma exacerbations, while no patient
in the FF 50 mcg group reported or was treated for a
severe asthma exacerbation. There were no reports of
pneumonia or oral/oropharyngeal candidiasis.Discussion
In patients with persistent asthma uncontrolled by non-ICS
medications, FF 50 mcg administered once daily in the
evening for 12 weeks significantly improved evening trough
FEV1 compared with placebo. Patients who received FF 50
mcg also showed a significant increase in the percentage of
rescue-free 24-h periods compared with placebo. The safety
profile for FF 50 mcg was acceptable and similar to that of
placebo. The patient population was chosen as the most
appropriate for once-daily treatment with a low dose of FF.
The statistically significant improvement in evening
trough FEV1 observed with FF 50 mcg compared with
placebo (120 mL) is similar to findings from a recent
Figure 5 Time to withdrawal due to lack of efficacy (intent-to-treat population). FF = fluticasone furoate; OD = once daily.
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doses of once-daily FF (25–200 mcg) for the treatment
of persistent asthma over 8 weeks [7]. The current study
was performed in a similar population of asthma patients
(i.e., those who required a step-up to Step 2 of asthma
treatment guidelines) and, although lung function at
baseline was different, those authors found that FF
50–200 mcg statistically significantly improved lung
function compared with placebo; the treatment difference
between FF 50 mcg and placebo in trough FEV1 was
129 mL (p < 0.033). The present data for FF, generated
from a larger cohort of patients and over a longer period
of time, support these findings [7]. The study was poweredTable 3 Summary of most frequent on-treatment AEs and
serious AEs (safety population)
n, % Placebo OD
PM (N = 121)
FF 50 mcg OD
PM (N = 121)
AEs
On treatment 46 (38) 37 (31)
On treatment, treatment-related 4 (3) 1 (<1)
On treatment, leading to withdrawal 1 (<1)a 0
Post treatment 1 (<1) 1 (<1)
Serious AEs
On treatmentb 1 (<1) 1 (<1)
On treatment AEs occurring in ≥3%
patients in either treatment group
Headache 14 (12) 6 (5)
Nasopharyngitis 5 (4) 7 (6)
Pharyngitis 6 (5) 6 (5)
Influenza 4 (3) 1 (<1)
aAn incidence of urticaria in one placebo-treated patient; btraffic accident,
placebo group; perforated appendix, FF 50 mcg group; AE = adverse event;
FF = fluticasone furoate; OD = once daily; PM = evening.based on a change in evening trough FEV1 of 200 mL.
However, in another study comparing morning and
evening dosing of FF/VI whose findings were reported
after our study design was finalized, smaller treatment
differences vs. placebo were seen for evening FEV1 when
compared with morning FEV1 – this was probably due to
the known diurnal variation in lung function [18]. Despite
this, the effect of FF 50 mcg on evening FEV1 in our
study was significant. However, in another phase III
study the improvement for FF 50 mcg over placebo was
not statistically significant, although improvement with
the active comparator fluticasone propionate (FP) 100 mcg
was significant (102 mL; p = 0.030) [14]. The reason for the
findings of Busse et al. not being consistent with those
of the current and previous studies of FF 50 mcg [7] is
unclear, as the patient population enrolled was very
similar to that of the current study. Finally, for the pow-
ered secondary endpoint in this study, the statistically
significant increase in the percentage of rescue-free 24-h
periods with FF 50 mcg compared with placebo is consist-
ent with results from the 8-week dose-ranging study that
involved FF 50 mcg [7]. Collectively, the findings suggest
that FF 50 mcg results in meaningful improvements in
trough FEV1 and percentage of rescue-free 24-h periods.
Statistical significance was not achieved for the sec-
ondary endpoint of change from baseline in evening PEF
for FF 50 mcg vs. placebo, meaning that significance
could not be inferred for the remaining secondary and
other endpoints. However, other studies investigating
treatment with FF 50 mcg [7,14] or FF 100 mcg [8] have
reported numerically greater improvements in evening
PEF compared with placebo (treatment differences of
20.7 L/min, 17.2 L/min and 15.9 L/min, respectively). Lung
function is generally improved in the evening due to diur-
nal variation [19], reducing the likelihood of detecting
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FEV1, which was also assessed in the evening, did improve
significantly following FF 50 mcg compared with placebo
treatment. For the remaining endpoints of morning PEF,
symptom-free 24-h periods, ACT score, percentage of
patients controlled (defined by ACT score ≥20 at Week 12)
and Total AQLQ score, numerically greater increases were
observed over 12 weeks in patients who received FF 50
mcg compared with placebo. More patients in the placebo
group were withdrawn due to lack of efficacy compared
with the FF 50 mcg group.
The overall safety profile was favorable in both the FF
50 mcg and placebo groups, consistent with previous
findings for this dose of FF [7,14]. Cortisol levels were
not measured in this study, as the treatment was with a
low dose of FF and no effect of cortisol had been seen
with higher doses. The effect of FF on cortisol levels
has been assessed in a separate meta-analysis, which is
published elsewhere [20]. Common AEs experienced by
asthma patients receiving ICS treatment included head-
ache, nasopharyngitis, pharyngitis and influenza. Incidence
of these AEs was similarly low between treatment groups
in this study, although headache was more frequent in the
placebo group.
A strength of our study is the inclusion of a statistical
hierarchy of endpoints, which added robustness in valid-
ating the overall efficacy of FF 50 mcg compared with
placebo. However, this might also be considered a weak-
ness, as failure to achieve statistical significance for evening
PEF meant that treatment differences between FF 50 mcg
and placebo for the remaining endpoints could only be
interpreted in descriptive terms. Another strength was the
use of electronic diary cards, which meant that all entries
were date and time stamped and which did not allow retro-
spective entries; this is likely to have increased the quality
of daily recordings.
Conclusions
In summary, FF 50 mcg administered once daily in the
evening significantly improved evening trough FEV1 and
the percentage of rescue-free 24-h periods compared with
placebo. Improvements with FF 50 mcg were numerically
greater than with placebo for all efficacy endpoints. Fewer
patients receiving FF 50 mcg treatment withdrew due to
lack of efficacy compared with patients receiving placebo
treatment and there were no safety concerns. Overall, the
efficacy/tolerability profile of FF 50 mcg was acceptable,
suggesting that treatment with FF 50 mcg is potentially
suitable for patients ≥12 years of age with persistent
asthma that is uncontrolled by non-ICS therapy.
Endnote
aELLIPTA™ is a trademark of the GlaxoSmithKline
group of companies.Abbreviations
ACT: Asthma control test™; AE: adverse events; ANCOVA: Analysis of
covariance; AQLQ: Asthma quality of life questionnaire; FEV1: forced
expiratory volume in one second; FF: Fluticasone furoate; ICS: Inhaled
corticosteroid; ITT: Intent-to-treat; LABA: Long-acting β2-agonist; PEF: Peak
expiratory force; SABA: Short-acting β2-agonists; VI: Vilanterol.
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